1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Peptide Therapeutics Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2020

Peptide Therapeutics Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2020

  • November 2015
  • -
  • Future Market Insight Global & Consulting Pvt Ltd
  • -
  • 111 pages

Future Market Insights offers a 6-year forecast of the global peptide therapeutics market between 2015 and 2020. In terms of value, the market is expected to register a CAGR of 2.9% during the forecast period. This study demonstrates market dynamics and trends in all seven regions that influence the current environment and future status of the peptide therapeutics market over the forecast period.

Report Description

This Future Market Insights report examines the peptide therapeutics market for the period 2015–2025. The primary objective of the report is to offer insights into developments in the peptide therapeutics market that are significantly transforming global businesses and enterprises.

The global peptide therapeutics market report begins with defining ‘what are peptides’ and the various drug classes using peptides with regard to various ailments. It is followed by an overview of the global peptide therapeutics market. The overview section includes FMI analysis of key trends, drivers, restraints, trends and opportunities that are influencing growth of the peptide therapeutics market. It also includes an insight into upcoming drug pipeline of various drug makers using peptides and market shares of major players, apart from region-specific regulations. Impact analyses of key growth drivers and restraints based on a weighted average model have been included in the ‘global peptide therapeutics market report’ to better equip customers and readers with region specific trends and insights.

The primary driving factors for peptide therapeutics are significant increase in cases of metabolic disorders such as diabetes, obesity, and osteoporosis. Further, increase in cancer incidences have also triggered the growth of the peptide therapeutics market. Research indicates that brain disorders including developmental, psychiatric and neurodegenerative diseases represent a significant disease burden in terms of human suffering and economic cost across the globe. These pump demand for peptide-based drugs for major ailments. The primary factor hampering growth of the peptide market is rising product complexity and lack of skilled labour to manufacture these drugs.

The global peptide therapeutics market is segmented based on disease indications. These include cancer. Respitaory, CNS, cardio-vascular, metabolic disorders and others. A detailed analysis has been provided for all ten categories of diseases and sub-segment in terms of market size, Y-o-Y growth rate, absolute $ opportunity and BPS analysis.

The report has also been segmented based on various drug administration channels such oral and parenteral. A deep analyses along with market attractiveness for each of the categories have been provided in the report

The next section of the report highlights the peptide therapeutics market by region. It provides a market outlook for 2014–2020 and sets the forecast within the context of the peptide therapeutics market. The study discusses key regional trends contributing to growth of the peptide therapeutics market worldwide, as well as analyses the extent to which drivers are influencing this market in each region. Key regions assessed in this report include North America, Europe, Asia Pacific and Rest of the world.

The above sections – by disease indication, route of administration and region – evaluate the present scenario and growth prospects of the peptide therapeutics market for the period 2014 –2020. We have considered 2014 as the base year and provide data for the forecast period, i.e. 2014–2020.

To ascertain the market size of peptide therapeutics, we have also considered revenue generated by drug manufacturers. The forecast presented here assesses the total revenue by value across the peptide therapeutics market. In order to offer an accurate forecast, we started by sizing the current market, which forms the basis of how the peptide therapeutics market is expected to develop in the future. Given the characteristics of the market, we triangulated the outcome of three different types of analysis, based on supply side, downstream industry demand and the economic envelope.

In addition, it is imperative to note that in an ever-fluctuating global economy, we not only conduct forecasts in terms of CAGR, but also analyse based on key parameters such as year-on-year (Y-o-Y) growth rates to understand the predictability of the market and to identify the right opportunities across the peptide therapeutics market.

The peptide therapeutics’ market segments in terms of disease indication, route of administration and region are analysed in terms of Basis Point Share (BPS) to understand individual segment’s relative contributions to market growth. This detailed level of information is important for identification of various key trends in the peptide therapeutics market.

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective of the peptide therapeutics market.

To understand key growth segments in terms of growth and adoption for the ten disease indications across the globe in the near future, Future Market Insights developed the peptide therapeutics market ‘Attractiveness Index’. The resulting index should help providers identify real market opportunities.

In the final section of the report on peptide therapeutics, ‘Competitive Landscape’ is included to provide report audiences with a dashboard view, based on categories of providers in the value chain of the peptide therapeutics product portfolio and key differentiators. Key categories of providers covered in the report are peptide therapeutics manufacturers. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the peptide therapeutics value chain and the potential players for the same. Report audiences can gain segment-specific vendor insights to identify and evaluate key competitors based on in-depth assessment of capabilities and successes in peptide therapeutics marketplace.

Detailed profiles of the drug makers are also included in the scope of the report to evaluate their long-term and short-term strategies, key offerings, SWOT analysis and recent developments. Key players include Amgen, Inc., AstraZeneca plc, Bachem Holding AG, Eli Lilly & Co., Ipsen, Lonza, Inc., Merck & Co., Novartis AG, Novo Nordisk A/S, Polypeptide Group, Roche Holding AG, Sanofi, Takeda Pharmaceutical Company Limited and Teva Pharmaceuticals Limited.

Key Segments Covered

Disease Indication
Cancer
CNS indications
Cardiovascular Diseases
Metabolic Diseases
Infections
Haematological disorders
Gastrointestinal Disorders
Respiratory Disorders
Acromegaly
Others (includes pain therapeutics, osteoporosis, etc.)
By Route of Drug Administration
Oral
Parenteral

Key Regions Covered

North America
Europe
Asia Pacific
Rest of World

Key Companies

Amgen, Inc.,
AstraZeneca plc,
Bachem Holding AG, Eli Lilly & Co.,
Ipsen,
Lonza, Inc.,
Merck & Co.,
Novartis AG,
Novo Nordisk A/S,
Polypeptide Group,
Roche Holding AG,
Sanofi,
Takeda Pharmaceutical Company Limited and
Teva Pharmaceuticals Limited

Table Of Contents

Peptide Therapeutics Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2020
Table Of Content

Chapter 1 Introduction

1.1 Report Description

1.2 Market Segmentation

1.3 Research Methodology

1.4 List of Abbreviations

1.5 Assumptions and Stipulations

Chapter 2 Executive Summary

2.1 Market Snapshot: Global Peptide Therapeutics Market (2014 and 2020)

2.2 Global Peptide Therapeutics Market, by Applications, 2014 (USD Million)

Chapter 3 Global Peptide Therapeutics Market Overview

3.1 Introduction

3.2 Emerging Trends in Peptide Therapeutics Market

3.2.1 Trends in Peptide Manufacturing Technology

3.2.2 Trends in Peptide API Supply

3.3 Market Dynamics

3.3.1 Drivers

3.3.1.1 Increase in cancer and diabetes patient population to propel the growth of new peptides

3.3.1.2 Rich RandD pipeline of peptide drugs is expected to drive growth

3.3.1.3 Technological advancements have reduced total production cost of peptides

3.3.2 Restraints

3.3.2.1 Increasing complexity of peptides is a huge challenge for API manufacturers

3.3.2.2 Lack of regulatory standards

3.3.3 Opportunities

3.3.3.1 Generic peptides market to flourish with patent cliff expected during the forecast period

3.3.3.2 Biotech firms collaborating with large pharmaceutical companies to explore further growth

3.4 Regulatory Scenario

3.5 Porter's Five Forces Analysis: Global Peptide Therapeutics Market

3.5.1 Bargaining Power of Suppliers

3.5.2 Bargaining Power of Buyer

3.5.3 Threat of Substitutes

3.5.4 Threat of New Entrants

3.5.5 Competitive Rivalry

3.6 Event Impact Analysis

3.6.1 Event Impact Analysis: Global Peptide Therapeutics Market

3.7 Market Attractiveness Analysis

3.7.1 Market Attractiveness Analysis of Global Peptide Therapeutics Market, by Geography, 2014

3.8 Market Share Analysis

Chapter 4 Global Peptide Therapeutics Market, by Applications

4.1 Introduction

4.1.1 Global Peptide Therapeutics Market Revenue, by Application, 2014 - 2020 (USD Million)

4.2 Cancer

4.2.1 Global Cancer Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

4.2.2 Zoladex (goserelin)

4.2.3 Velcade (bortezomib)

4.2.4 Lupron/ Enantone/ Eligard (leuprorelin)

4.2.5 Others

4.3 Cardiovascular

4.3.1 Global Cardiovascular Disorders Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

4.3.2 Angiomax (bivalirudin)

4.3.3 Integrilin (eptifibatide)

4.4 Central Nervous System

4.4.1 Global Central Nervous System Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

4.4.2 Copaxone (glatiramer)

4.5 Metabolic Disorders

4.5.1 Global Metabolic Disorders Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

4.5.2 Victoza (liraglutide)

4.5.3 Byetta (exenatide)

4.5.4 Others

4.6 Infection

4.6.1 Global Infection Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

4.6.2 Incivek (telaprevir)

4.6.3 Victrelis (boceprevir)

4.7 Hematological Disorders

4.7.1 Global Hematological Disorders Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

4.7.2 Firazyr (icatibant)

4.7.3 Kalbitor (ecallantide)

4.8 Gastrointestinal Disorders

4.8.1 Global Gastrointestinal Disorders Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

4.8.2 Gattex (teduglutide)

4.8.3 Linzess (linaclotide)

4.9 Respiratory Disorders

4.9.1 Global Respiratory Disorders Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

4.10 Acromegaly

4.10.1 Global Acromegaly Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

4.11 Other Applications

4.11.1 Global Other Applications Peptide Therapeutics market Revenue, 2014 - 2020 (USD Million)

Chapter 5 Global Peptide Therapeutics Market, by Route of Administration

5.1 Introduction

5.1.1 Global Peptide Therapeutics Market Revenue, by Route of Administration, 2014 - 2020 (USD Million)

5.2 Parenteral Route of Administration

5.2.1 Global Peptide Therapeutics Market Revenue, by Parenteral Route of Administration, 2014 - 2020 (USD Million)

5.3 Oral Route of Administration

5.3.1 Global Peptide Therapeutics Market Revenue, by Oral Route of Administration, 2014 - 2020 (USD Million)

Chapter 6 Global Peptide Therapeutics Market, by Marketing Status

6.1 Introduction

6.1.1 Global Peptide Therapeutics Market Revenue, by Marketing Status, 2014 - 2020 (USD Million)

6.2 Branded Peptide Therapeutics

6.2.1 Global Branded Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

6.3 Generic Peptide Therapeutics

6.3.1 Global Generic Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

Chapter 7 Global Peptide Therapeutics Pipeline Overview

7.1 Introduction

7.1.1 Global Peptide Therapeutics Pipeline Overview

Chapter 8 Global Peptide Therapeutics Market, by Geography

8.1 Introduction

8.1.1 Global Peptide Therapeutics Market Revenue, by Geography, 2014 - 2020 (USD Million)

8.2 North America

8.2.1 North America Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

8.3 Europe

8.3.1 Europe Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

8.4 Asia Pacific

8.4.1 Asia Pacific Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

8.5 Rest of the World

8.5.1 Rest of the World Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

Chapter 9 Recommendations

9.1 Rigorous research and development (RandD) would yield new products

9.2 Facility expansion in emerging economies

9.3 Rapid inorganic growth through acquisitions

Chapter 10 Company Profiles

10.1 Amgen, Inc.

10.1.1 Company Overview

10.1.2 Financial Overview

10.1.3 Product Portfolio

10.1.4 Business Strategies

10.1.4.1 Mergers and acquisitions

10.1.5 Recent Developments

10.2 AstraZeneca plc

10.2.1 Company Overview

10.2.2 Financial Overview

10.2.3 Product Portfolio

10.2.4 Business Strategies

10.2.4.1 Acquisitions and collaborations

10.2.5 Recent Developments

10.3 Bachem Holding AG

10.3.1 Company Overview

10.3.2 Financial Overview

10.3.3 Product Portfolio

10.3.4 Business Strategies

10.3.4.1 Focus on profitable segments for market expansion and development

10.3.5 Recent Developments

10.4 CordenPharma International GmbH

10.4.1 Company Overview

10.4.2 Financial Overview

10.4.3 Product Portfolio

10.4.4 Business Strategies

10.4.4.1 Gaining competitive edge through compliance with regulatory authorities

10.4.4.2 Mergers and Acquisitions

10.4.5 Recent Developments

10.5 Eli Lilly and Company

10.5.1 Company Overview

10.5.2 Financial Overview

10.5.3 Product Portfolio

10.5.4 Business Strategies

10.5.4.1 Extensive RandD activities

10.5.4.2 Collaborations and agreements

10.5.5 Recent Developments

10.6 Ipsen S.A.

10.6.1 Company Overview

10.6.2 Financial Overview

10.6.3 Product Portfolio

10.6.4 Business Strategies

10.6.4.1 Mergers and Acquisitions

10.6.5 Recent Developments

10.7 Lonza Group Ltd.

10.7.1 Company Overview

10.7.2 Financial Overview

10.7.3 Product Portfolio

10.7.4 Business Strategies

10.7.4.1 Divestiture Strategies

10.7.4.2 Strategic Agreements

10.7.5 Recent Developments

10.8 Merck and Co., Inc.

10.8.1 Company Overview

10.8.2 Financial Overview

10.8.3 Product Portfolio

10.8.4 Business Strategies

10.8.4.1 Mergers and acquisitions

10.8.4.2 Strategic collaborations

10.8.4.3 Expansion in emerging markets

10.8.5 Recent Developments

10.9 Novartis AG

10.9.1 Company Overview

10.9.2 Financial Overview

10.9.3 Product Portfolio

10.9.4 Business Strategies

10.9.4.1 Product pipeline expansion

10.9.5 Recent Developments

10.10 Novo Nordisk A/S

10.10.1 Company Overview

10.10.2 Financial Overview

10.10.3 Product Portfolio

10.10.4 Business Strategies

10.10.4.1 Dominance in diabetes portfolio

10.10.5 Recent Developments

10.11 PolyPeptide Group

10.11.1 Company Overview

10.11.2 Financial Overview

10.11.3 Product Portfolio

10.11.4 Business Strategies

10.11.5 Recent Developments

10.12 Roche Holdings AG

10.12.1 Company Overview

10.12.2 Financial Overview

10.12.3 Product Portfolio

10.12.4 Business Strategies

10.12.4.1 Consistent product launches

10.12.4.2 Mergers and Acquisitions

10.12.5 Recent Developments

10.13 Sanofi

10.13.1 Company Overview

10.13.2 Financial Overview

10.13.3 Product Portfolio

10.13.4 Business Strategies

10.13.4.1 Collaborations

10.13.5 Recent Developments

10.14 Takeda Pharmaceutical Company Limited

10.14.1 Company Overview

10.14.2 Financial Overview

10.14.3 Product Portfolio

10.14.4 Business Strategies

10.14.4.1 Growth in emerging markets

10.14.4.2 Strategic collaborations and agreements

10.14.5 Recent Developments

10.15 Teva Pharmaceutical Industries Ltd.

10.15.1 Company Overview

10.15.2 Financial Overview

10.15.3 Product Portfolio

10.15.4 Business Strategies

10.15.4.1 Strengthening foundation and driving organic growth

10.15.4.2 Focusing on Copaxone and other key specialty products

1.1 10.15.5 Recent Developments
List of Tables

TABLE 1 Market Snapshot: Global Peptide Therapeutics Market (2014 and 2020)

TABLE 2 Event Impact Analysis: Global Peptide Therapeutics Market

TABLE 3 Global Peptide Therapeutics Market Revenue, by Application, 2014 - 2020 (USD Million)

TABLE 4 Global Cancer Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

TABLE 5 Global Cardiovascular Disorders Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

TABLE 6 Global Metabolic Disorders Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

TABLE 7 Global Infection Disorders Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

TABLE 8 Global Hematological Disorders Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

TABLE 9 Global Gastrointestinal Disorders Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

TABLE 10 Global Acromegaly Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

TABLE 11 Global Peptide Therapeutics Market Revenue, by Route of Administration, 2014 - 2020 (USD Million)

TABLE 12 Global Peptide Therapeutics Market Revenue, by Marketing Status, 2014 - 2020 (USD Million)

TABLE 13 Global Peptide Therapeutics Market Pipeline Overview

TABLE 14 Global Peptide Therapeutics Market Revenue, by Geography, 2014 - 2020 (USD Million)
List of Figures

FIG. 1 Peptide Therapeutics Market Segmentation

FIG. 2 Global Peptide Therapeutics Market, by Applications, 2014 (USD Million)

FIG. 3 Porter's Five Forces Analysis: Global Peptide Therapeutics Market

FIG. 4 PEST Analysis North America and Europe

FIG. 5 Market Attractiveness Analysis of Global Peptide Therapeutics Market, by Geography, 2014

FIG. 6 Market Share Analysis of Global Peptide Therapeutics Market, by Key Players, 2014 (Value %)

FIG. 7 Global Central Nervous System Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

FIG. 8 Global Respiratory Disorders Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

FIG. 9 Global Other Applications Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

FIG. 10 Global Peptide Therapeutics Market Revenue, by Parenteral Route of Administration, 2014 - 2020 (USD Million)

FIG. 11 Global Peptide Therapeutics Market Revenue, by Oral Route of Administration, 2014 - 2020 (USD Million)

FIG. 12 Global Branded Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

FIG. 13 Global Generic Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

FIG. 14 North America Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

FIG. 15 Europe Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

FIG. 16 Asia Pacific Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

FIG. 17 Rest of the World Peptide Therapeutics Market Revenue, 2014 - 2020 (USD Million)

FIG. 18 Amgen, Inc: Annual Revenue, 2014 - 2014 (USD Million)

FIG. 19 AstraZeneca plc: Annual Revenue, 2014 - 2014 (USD Million)

FIG. 20 Bachem Holding AG: Annual Revenue, 2014 - 2014 (USD Million)

FIG. 21 Eli Lilly and Company: Annual Revenue, 2014 - 2014 (USD Million)

FIG. 22 Ipsen S.A.: Annual Revenue, 2014 - 2014 (USD Million)

FIG. 23 Lonza Group Ltd.: Annual Revenue, 2014 - 2014 (USD Million)

FIG. 24 Merck and Co., Inc.: Annual Revenue, 2014 - 2014 (USD Million)

FIG. 25 Novartis AG Annual Revenue: 2014 - 2014 (USD Million)

FIG. 26 Novo Nordisk A/S Annual Revenue: 2014 - 2014 (USD Million)

FIG. 27 Roche Holdings AG: Annual Revenue: 2014 - 2014 (USD Million)

FIG. 28 Sanofi: Annual Revenue, 2014 - 2014 (USD Million)

FIG. 29 Takeda Pharmaceutical Co. Ltd.: Annual Revenue: 2014 - 2014 (USD Million)

FIG. 30 Teva Pharmaceutical Co. Ltd.: Annual Revenue: 2014 - 2014 (USD Million)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...


Download Unlimited Documents from Trusted Public Sources

Global Salicylic Acid Market

  • January 2017
    16 pages
  • Salicylic Acid  

  • World  

View report >

Cancer Statistics in Denmark

  • January 2017
    6 pages
  • Therapy  

  • Denmark  

View report >

Anti-Infective Market in India

  • January 2017
    4 pages
  • Anti-Infective  

    Blood Disease  

  • India  

    United States  

View report >

Related Market Segments :

Therapy

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.